Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 15, Issue 2, 2010, Pages 253-260

  Creighton, Chad J ^a   Chang, Jenny C ^a   Rosen, Jeffrey M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer stem cells; EMT. Epithelial mesenchymal transition; Tumorigenic cells

Indexed keywords

LETROZOLE; NOTCH RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; ANTINEOPLASTIC AGENT; CLAUDIN; DIFFERENTIATION ANTIGEN;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL MATURATION; CELL REGENERATION; CELL TYPE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; REVIEW; STEM CELL; TUMOR INITIATING CELL; ANIMAL; BREAST NEOPLASMS; CELL DEDIFFERENTIATION; CELL TRANSDIFFERENTIATION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MESENCHYMAL STROMA CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DEDIFFERENTIATION; CELL TRANSDIFFERENTIATION; CLAUDINS; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MESENCHYMAL STEM CELLS; MESENCHYMAL STROMAL CELLS;

EID: 77954861745     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-010-9173-1     Document Type: Review

References (46)

1. Vargo-Gogola T, Rosen J. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7:659-72.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74.
3. Visvader J, Lindeman G. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-68.
4. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-8.
5. Li X, Lewis M, Huang J, Gutierrez C, Osborne C, Wu M, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672-9.
6. Creighton C, Li X, Landis M, Dixon J, Neumeister V, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106(33):13820-5.
7. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoetic cell. Nat Med. 1997;3:730-7.
8. Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-5.
9. Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
10. Dontu G, Abdallah W, JM F, Jackson K, Clarke M, Kawamura M, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253-70.
11. Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605-15.
12. Dontu G, Al-Hajj M, Abdallah W, Clarke M, Wicha M. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(suppl-1):59-72.
13. Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-60.
14. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir I, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
15. Jones R, Matsui W, Smith B. Cancer stem cells: are we missing the target? J Natl Cancer Inst. 2004;96(8):583-5.
16. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100 (14):8418-23.
17. Herschkowitz J, Simin K, Weigman V, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.16.
18. Hennessy B, Gonzalez-Angulo A, Stemke-Hale K, Gilcrease M, Krishnamurthy S, Lee J, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116-24.
19. Liu R, Wang X, Chen G, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217-26.
20. Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259-73.
21. van de Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
22. Lim E, Vaillant F, Wu D, Forrest N, Pal B, Hart A, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907-13.
23. Guarino M, Rubino B, Ballabio G The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305-18.
24. Damonte P, Gregg J, Borowsky A, Keister B, Cardiff R. EMT tumorigenesis in the mouse mammary gland. Lab Invest. 2007;87:1218-26.
25. Kokkinos M, Wafai R, Wong M, Newgreen D, Thompson E, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer\observations in vitro and in vivo. Cells Tissues Organs. 2007;185:191-203.
26. Lee J, Dedhar S, Kalluri R, Thompson E. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973-81.
27. Sarrio D, Rodriguez-Pinilla S, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989-97.
28. Trimboli A, Fukino K, de Bruin A, Wei G, Shen L, Tanner S, et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008;68:937-45.
29. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682-8.
30. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68 (4):989-97.
31. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008;68(3):937-45.
32. Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592-603.
33. Gregory P, Bracken C, Bert A, Goodall G. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008;7(20):3112-8.
34. Wellner U, Schubert J, Burk U, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(12):1487-95.
35. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal. 2009;2(92):ra62.
36. Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-15.
37. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA. 2007;104(24):10069-74.
38. Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645-59.
39. Huber M, Kraut N, Beug H. Molecular requirements for epithelial- mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548-58.
40. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 2004;15 (5):193-7.
41. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605-15.
42. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2005;1(3):207-13.
43. Dontu G, Wicha MS. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia. 2005;10(1):75-86.
44. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005;7(3):86-95.
45. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA. 2008;105 (5):1680-5.
46. Korkaya H, Paulson A, Iovino F, Wicha M. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27(47):6120-30.